Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

Targeted therapies such as Cyclin Dependent Kinase 4 and 6 (CDK 4/6) inhibitors have improved the prognosis of metastatic hormone receptor (HR) positive breast cancer by combating the resistance seen with traditional endocrine therapy. The three approved agents currently in the market are palbocicli...

Full description

Bibliographic Details
Main Authors: Mridula A. George, Sadaf Qureshi, Coral Omene, Deborah L. Toppmeyer, Shridar Ganesan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
metastatic breast cancer
CDK4/6 cell cycle inhibitors
hormone receptor (HR)
palbociblib
ribociclib
abemaciclib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.693104/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.693104/full

Similar Items